New Risk • Aug 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$9.6m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Duyuru • Aug 11
Alamar Biosciences, Inc. Provides Revenue Guidance for the Full Year 2026 Alamar Biosciences, Inc. provided revenue guidance for the full year 2026. For the period, the company expects revenue to be in the range of $116 million to $120 million, representing growth of 59% at the midpoint of the range compared to full year 2025. Canlı Haber • Jul 30
Alamar Biosciences Unveils NULISAseq Immune 340 Panel for Expanded Disease Research Alamar Biosciences launched the NULISAseq Immune 340 Panel, its broadest multiplexed immune profiling product so far, enabling measurement of about 340 immune-related proteins from a single sample for translational research and drug development.
The new panel extends the earlier NULISAseq Inflammation Panel 250 and is aimed at research in cancer, cardiovascular and metabolic diseases, autoimmune conditions, and aging. This broadens the range of disease areas addressable on Alamar’s platform.
Alamar Biosciences shares recently traded at about US$24.37, with the stock down roughly 12.2% over the past 30 days.
This launch signals that Alamar Biosciences is investing in a wider suite of immune proteome tools, which could deepen adoption among researchers focused on complex disease biology. From an investment perspective, a richer panel may help the company capture more workflows within existing customers and appeal to new labs that need high-plex immune profiling, although actual commercial traction and pricing will be important factors to monitor. Duyuru • Jul 29
Alamar Biosciences Launches NULISAseq Immune 340 Panel For Comprehensive Profiling Of The Immune Proteome Alamar Biosciences, Inc. announced the launch of the NULISAseq Immune 340 Panel, its broadest multiplexed immune profiling solution available for translational research and drug development. The panel expands on the NULISAseq Inflammation Panel 250, to deliver simultaneous measurement of approximately 340 immune-related proteins from a single sample. By measuring key proteins that were previously undetectable by other methods, the Immune 340 Panel deepens the understanding of the immune proteome in critical disease areas across cancer, cardiovascular and metabolic diseases, autoimmune diseases, and aging research. Highly sensitive multiplex measurement captures regulatory proteins, like checkpoint inhibitors, and low abundance targets that standard platforms routinely miss. Immune responses are never driven by a single protein. Pathway crosstalk, feedback loops, and cell type cooperation all demand multi-protein context to interpret. Understanding this biology, and catching it early, requires measuring the cytokines and other biomarkers of immune activation that signal disease before symptoms appear. The challenge is detection. Many immune mediators, including cytokines, chemokines, and cell death pathway markers, circulate at fg/mL to sub-pg/mL concentrations, well below the floor of conventional immunoassays. This is especially true of inflammaging, the chronic, low-grade inflammation that builds quietly with age as immune senescence and neuroimmune activation compound to drive cardiovascular, metabolic, neurodegenerative, and cancer risk. Its key signals have largely been invisible to researchers until now. In drug development, the ability to simultaneously profile the full immune landscape – not just the well-characterized cytokines, but the entire network of checkpoints, metabolic regulators, cell death mediators, and co-stimulatory signals – fundamentally changes what can be learned from a single sample. What makes the NULISAseq Immune 340 Panel distinctive is the combination of breadth and sensitivity. Many of the proteins most relevant to immune mechanisms of action, resistance, and toxicity have historically been undetectable in blood. Having access to them, alongside the canonical markers, in one multiplexed run opens new possibilities for biomarker discovery and patient stratification. Canlı Haber • Jul 25
Alamar Biosciences Secures Rights to Use pTau217 Antibody in Alzheimer’s Diagnostics ALZpath and Alamar Biosciences have expanded their agreement to cover clinical diagnostics, granting Alamar commercial rights to use ALZpath’s proprietary pTau217 antibody in blood-based tests intended for Alzheimer’s disease diagnosis.
The broadened deal allows Alamar to apply the pTau217 antibody in both research and clinical environments, which could support wider use of blood biomarkers as an alternative to more invasive or complex Alzheimer’s diagnostic tools.
Alamar Biosciences’ stock trades at $25.88, with the share price up 17.6% year to date.
Bringing a clinically focused pTau217 antibody into Alamar Biosciences’ test line-up could strengthen its position in Alzheimer’s diagnostics, but it also raises execution questions around assay performance, regulatory pathways and eventual clinical uptake that readers may wish to factor into their risk view. Duyuru • Jul 16
Alamar Biosciences, Inc. Announces Board and Committee Changes Alamar Biosciences, Inc. was deeply saddened to report that Ian Ratcliffe, a member of the Company's board of directors, passed away on July 5, 2026. Ian Ratcliffe served as an independent director on the Board since February 2024. Following Ian Ratcliffe's passing, the Board decreased the number of authorized directors constituting the full Board to five and appointed Nicholas Naclerio, Ph.D., to the Audit Committee of the Board. Duyuru • Jul 15
Alamar Biosciences, Inc. to Report Q2, 2026 Results on Aug 10, 2026 Alamar Biosciences, Inc. announced that they will report Q2, 2026 results After-Market on Aug 10, 2026 Canlı Haber • Jul 14
Alamar Biosciences Joins Major University Effort on Nationwide Neurodegenerative Biomarker Study Alamar Biosciences is partnering with leading research universities on a national proteomics initiative that will use its NULISAseq Neuro 220 panel to profile about 21,000 plasma samples from 10,000 participants for blood-based biomarkers linked to Alzheimer’s and other neurodegenerative diseases.
The project will create a large, publicly accessible dataset tied to National Alzheimer’s Coordinating Center IDs and is part of Alamar’s CLARiTI portfolio, with plans for a national AI-focused data challenge to support discovery.
Alamar Biosciences shares trade at US$27.40, with the stock up 24.5% over the past 30 days.
Having its Neuro 220 panel embedded in a national, open-data effort could help Alamar Biosciences build credibility in neurobiology tools and AI-driven biomarker discovery, while also exposing the platform to a broad base of academic and clinical users. Duyuru • Jul 13
Alamar Biosciences Partners With Research Universities To Launch National Proteomics Initiative Using NULISAseq Neuro 220 Panel Alamar Biosciences partnered with research universities to launch a national-scale proteomics initiative using Alamar Biosciences’ NULISAseq Neuro 220 panel to accelerate biomarker discovery and validation for Alzheimer’s disease and related neurodegenerative conditions. The project is co-led by professors Sarah Biber, PhD, at Washington University in St. Louis; Sterling Johnson, PhD, at the University of Wisconsin; and Tatiana Foroud, PhD, director of the National Centralized Repository for Alzheimer’s Disease and Related Dementias (NCRAD) at Indiana University. The project will generate large-scale plasma proteomic data from approximately 21,000 samples collected from 10,000 Alzheimer’s Disease Research Center (ADRC) participants across the United States. Samples are stored at NCRAD, providing a centralized national infrastructure for coordinated access and biomarker generation at scale. Profiling will use Alamar Biosciences’ NULISAseq Neuro 220 panel, enhanced with a newly added eMTBR-Tau assay that enables simultaneous blood-based representation of tau tangle burden alongside a broad panel of neurodegeneration and neuroinflammation biomarkers. The panel also offers the largest number of brain-derived Tau targets along with assays relevant to alpha-synuclein biology and other protein aggregation markers, creating a unique opportunity to study multiple neurodegenerative disease pathways in the same deeply characterized participants. The project is part of the CLARiTI portfolio and leverages its infrastructure to support coordinated sample access and harmonized data workflows. The effort has been advanced through sustained partnerships with the Alzheimer’s Association, the Robertson Foundation, an anonymous foundation, and important implementation and data-sharing support from the Alzheimer’s Disease Data Initiative. All data generated through the initiative will be made freely available to the global research community. A central goal is the creation of an open, publicly accessible proteomic dataset linked to National Alzheimer’s Coordinating Center (NACC) IDs. This linkage will allow researchers to connect the new proteomic profiles with rich longitudinal data available through the ADRC Program, including clinical, cognitive, neuroimaging, genetic, genomic, fluid biomarker, and neuropathology data. AI and computational teams will apply multimodal approaches for disease classification, biomarker discovery, and prediction of neurodegenerative disease progression. The next phase of the project will include a national data challenge inviting the broader research community to develop and test new analytical methods using this resource. Canlı Haber • Jul 08
Alamar Biosciences Unveils First Multiplexed Immunoassay Targeting Alzheimer’s eMTBR-Tau Biomarker Alamar Biosciences has launched the first commercial multiplexed blood-based immunoassay for the Alzheimer’s biomarker eMTBR-Tau, available within its NULISAseq Neuro 220 panel kits and as a single-plex test through its Technology Access Program, with new clinical data slated for presentation at AAIC 2026.
The eMTBR-Tau assay targets a plasma biomarker tied to tau tangle pathology and Alzheimer’s progression, expanding Alamar Biosciences’ neuro-focused offering and providing researchers with a more precise tool to measure disease-related tau biology.
Alamar Biosciences’ stock trades at $25.23, with the share price up 22.8% over the past 30 days.
This launch puts more attention on Alamar Biosciences’ role in Alzheimer’s research tools, and investor outcomes will depend on how widely researchers and partners adopt the eMTBR-Tau assay and whether it leads to durable assay demand. Duyuru • Jul 08
Alamar Biosciences Launches the First Multiplexed Blood-Based Immunoassay for eMTBR-Tau Alamar Biosciences, Inc. launched the first commercial eMTBR-Tau immunoassay, now available in the NULISAseq Neuro 220 multiplexed panel kits, deployable on the entire installed base of ARGO HT instruments, and as a single-plex assay through the company’s Technology Access Program. The assay measures eMTBR-Tau, a plasma biomarker that specifically reflects tau tangle pathology and has demonstrated strong associations with cognitive decline, clinical disease staging, and therapeutic response monitoring for Alzheimer’s disease. Immunoassay for eMTBR-Tau is available in the NULISAseq Neuro 220 panel and as a single-plex assay through the Technology Access Program. eMTBR-Tau offers a non-invasive, blood-based measurement of the tau tangle burden, the core pathology associated with disease progression and cognitive decline in Alzheimer’s disease. A definitive diagnosis of Alzheimer’s disease requires evidence of two hallmark pathologies: amyloid plaques and tau neurofibrillary tangles. Until recently, only one of these could be measured in blood: pTau-217, which serves as an indicator of amyloid pathology. However, a positive pTau-217 result alone is insufficient for a confirmatory diagnosis, as many individuals with amyloid accumulation have not yet developed tau tangles. Historically, measuring tau tangle burden required tau PET imaging, a method that is accurate but expensive and operationally complex. Recent studies have shown that a blood-based eMTBR-tau243 assay, based on mass spectrometry, correlates strongly with tau tangle burden, making it a promising blood-based surrogate for tau PET imaging. Alamar’s NULISA platform delivers a broadly accessible eMTBR-Tau assay that specifically targets the MTBR fragment that is generated by endogenous cleavage at site 256. The highly scalable assay measures eMTBR-Tau at attomolar sensitivity, multiplexed with other key neurodegeneration and neuroinflammation biomarkers from a single low volume sample. Beyond diagnosis, the close association between eMTBR-Tau levels and tau tangle burden may allow researchers to directly measure biological response to tau-targeted therapies and address a critical unmet need for a blood-based biomarker of treatment efficacy. Alamar will showcase eMTBR-Tau data at its workshop at the Alzheimer’s Association International Conference 2026 in London on Tuesday, July 14, where researchers will present performance results and clinical findings from studies using the NULISA platform. The workshop will include presentations covering the assay’s analytical performance, correlation with tau PET imaging, and the ability to stratify patients across Alzheimer’s disease stages. The NULISAseq Neuro 220 Panel with eMTBR-Tau is available now. Canlı Haber • Jun 04
Alamar Biosciences Launches Home Fingerstick Kit for Ultra Sensitive Multiplex Proteomics Assays Alamar Biosciences launched the NULISA Dried Blood Spot (DBS) Extraction Kit, allowing its ultra high-sensitivity, multiplex proteomics assays to run on small fingerstick blood samples collected at home.
The kit is designed to support longitudinal and decentralized translational studies in neurology, inflammation and population health.
The company positions this DBS capability as a way to make proteomics more accessible for population-based screening programs and remote sample collection.
This move pushes Alamar’s platform further into remote and decentralized research workflows, which can matter for adoption by academic centers, contract research groups and potential biopharma partners.
Investors may want to watch how quickly the DBS kit is incorporated into real-world studies, since usage levels and reference customers could become key indicators of commercial traction for Alamar’s technology. Duyuru • Jun 03
Alamar Biosciences Launches Nulisa Dried Blood Spot Extraction Kit Alamar Biosciences, Inc. launched the NULISA Dried Blood Spot (DBS) Extraction Kit, enabling researchers to run NULISA assays on microsamples collected at home, unlocking longitudinal and decentralized translational study designs in neurology, inflammation, and population health that cannot be supported by venous blood draws alone. NULISA DBS Extraction Kit recovers proteins from dried blood spot and dried plasma spot microsamples collected on leading third-party remote sampling devices. Dried blood spot sampling turns a few drops of blood into a dried, ambient-shippable specimen. For proteomics, it has been challenging for researchers to recover protein signals from extremely small sample volumes, across different collection devices, without losing the low-abundance biology they are trying to measure. The NULISA DBS Extraction Kit addresses these challenges with a standardized workflow for multiplex protein measurement from blood samples, collected on remote sampling devices and shipped at ambient temperature. The workflow connects remote sample collection to Alamar’s NULISA technology, enabling ultra-sensitive detection of low-abundance protein biomarkers in non-invasive biofluids. The NULISA platform offers ultra-high sensitivity, high specificity, flexible multiplexing, a broad dynamic range, and automated workflows. In validation studies, Alamar demonstrated 85–95% target detectability across its NULISA CNS and Inflammation panels on most supported microsampling platforms. The combination of the ARGO HT instrument design and the simplified collection and transport of dried blood spot microsamples unlocks proteomics in settings where it hasn't been practical, such as specialty clinics, regional labs, and point-of-care environments. The NULISA DBS Extraction Kit standardizes protein extraction across dried blood spot and dried plasma spot microsamples collected on leading third-party microsampling devices, including Capitainer, Telimmune, Mitra, and Tasso. The NULISA DBS Extraction Kit is now available. New Risk • May 17
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$67m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$67m free cash flow). Shares are highly illiquid. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$32m net loss in 3 years). Reported Earnings • May 14
First quarter 2026 earnings released First quarter 2026 results: US$1.74 loss per share. Net loss: US$21.3m (flat on 1Q 2025). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Life Sciences industry in the US. Duyuru • May 01
Alamar Biosciences, Inc. to Report Q1, 2026 Results on May 08, 2026 Alamar Biosciences, Inc. announced that they will report Q1, 2026 results Pre-Market on May 08, 2026 Duyuru • Apr 18
Alamar Biosciences, Inc. has completed an IPO in the amount of $191.25 million. Alamar Biosciences, Inc. has completed an IPO in the amount of $191.25 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 11,250,000
Price\Range: $17
Discount Per Security: $1.19
Transaction Features: Sponsor Backed Offering 